Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study
In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoprox...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-11, Vol.16 (11), p.e0260007-e0260007 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0260007 |
|---|---|
| container_issue | 11 |
| container_start_page | e0260007 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Jianu, Cristian Itu-Mureşan, Corina Drugan, Cristina Filipescu, Irina Topan, Adriana Violeta Jianu, Mihaela Elena Morar, Ioana Iulia Bolboacă, Sorana D |
| description | In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoproxil or Lamivudine/Tenofovir disoproxil, NRTI) on four interleukins (IL-4, IL-10, IL-13, and IL-21) as immune activation markers in naïve HIV(Human Immunodeficiency Virus)-infected patients during the first six months of combined standard-of-care antiretroviral therapy (cART). Newly diagnosed with HIV-infected subjects and without any disease that could affect the immune activation markers were evaluated. The patients' physicians recommended the cART as standard-of-care and the ILs were measured before cART and six months of cART. The levels of CD4+ T-cells count and CD4+/CD8+ ratio significantly increased at six months (P-value1 was observed in 25% of patients treated with Raltegravir and half of those treated with Dolutegravir. At six months of cART, viral load was detectable in only 6/31 individuals. IL-21 had an undetectable level in 30/31 patients after six months of cART. Our results suggest the potency in restoring immune markers in HIV-infected patients with all investigated drugs. Dolutegravir showed a tendency to statistically significant changes in IL-4 and IL-10. A clinical trial with random allocation of medication and an extensive follow-up is needed to replicate this research and validate the usefulness of evaluated ILs as markers of cART effectiveness. |
| doi_str_mv | 10.1371/journal.pone.0260007 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2598064206</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A682753022</galeid><doaj_id>oai_doaj_org_article_1917fccefd974944a0669bab8edc4dc9</doaj_id><sourcerecordid>A682753022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c641t-1641cfe9822d43b76be44fa1c2cffea4e84f708d02a1bbbdc2a0be5813ac547b3</originalsourceid><addsrcrecordid>eNqNk81u1DAQxyMEomXhDRBYQkJw2MV2nMThgLSqCl2pUiU-erUcZ7Lr1okX21nRC6_EQ_BiOGxabVAPKFLsjH__mcyMJ0meE7wgaUHeXdneddIstraDBaY5xrh4kByTMqXznOL04cH-KHni_RXGWcrz_HFylLKCs7Tkx8nP0500vQzadsg2yMMOnDRxdX2LdBfAGeivdeeR9KiV7hqcR411KDiQoYUuIGgaUEHvoAPvowZ18vevHaCz1WX8Gs6gRtsYIsL-PVqirTY2IB_6-uZp8qiRxsOzcZ0l3z6efj05m59ffFqdLM_nKmckzEl8qwZKTmnN0qrIK2CskURRFYNLBpw1BeY1ppJUVVUrKnEFGSepVBkrqnSWvNz73RrrxVg6L2hWcpwzivNIrPZEbeWV2Dodk70RVmrx12DdWkgXtDIgSEmKRilo6rJgJWMS53lZyYpDrVityujrwxitr9pojInHok6cTk86vRFruxM8KxmP_Zolb0YHzn7vwQfRaq_AGNmB7ff_nTGSZQP66h_0_uxGai1jArErNsZVg1OxzDktshRTGqnFPVR8ami1ives0dE-EbydCCIT4EdYy957sfry-f_Zi8sp-_qA3YA0YeOt6Ydr6qcg24PKWe8dNHdFJlgMY3JbDTGMiRjHJMpeHDboTnQ7F-kfNtAQvQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598064206</pqid></control><display><type>article</type><title>Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Jianu, Cristian ; Itu-Mureşan, Corina ; Drugan, Cristina ; Filipescu, Irina ; Topan, Adriana Violeta ; Jianu, Mihaela Elena ; Morar, Ioana Iulia ; Bolboacă, Sorana D</creator><contributor>Apetrei, Cristian</contributor><creatorcontrib>Jianu, Cristian ; Itu-Mureşan, Corina ; Drugan, Cristina ; Filipescu, Irina ; Topan, Adriana Violeta ; Jianu, Mihaela Elena ; Morar, Ioana Iulia ; Bolboacă, Sorana D ; Apetrei, Cristian</creatorcontrib><description>In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoproxil or Lamivudine/Tenofovir disoproxil, NRTI) on four interleukins (IL-4, IL-10, IL-13, and IL-21) as immune activation markers in naïve HIV(Human Immunodeficiency Virus)-infected patients during the first six months of combined standard-of-care antiretroviral therapy (cART). Newly diagnosed with HIV-infected subjects and without any disease that could affect the immune activation markers were evaluated. The patients' physicians recommended the cART as standard-of-care and the ILs were measured before cART and six months of cART. The levels of CD4+ T-cells count and CD4+/CD8+ ratio significantly increased at six months (P-value<0.02) regardless of the drugs, INSTIs or PI. However, a CD4+/CD8+ >1 was observed in 25% of patients treated with Raltegravir and half of those treated with Dolutegravir. At six months of cART, viral load was detectable in only 6/31 individuals. IL-21 had an undetectable level in 30/31 patients after six months of cART. Our results suggest the potency in restoring immune markers in HIV-infected patients with all investigated drugs. Dolutegravir showed a tendency to statistically significant changes in IL-4 and IL-10. A clinical trial with random allocation of medication and an extensive follow-up is needed to replicate this research and validate the usefulness of evaluated ILs as markers of cART effectiveness.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0260007</identifier><identifier>PMID: 34784398</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; Anti-HIV agents ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Antiviral agents ; Antiviral Agents - administration & dosage ; Antiviral Agents - pharmacology ; Bacterial infections ; Biology and Life Sciences ; Biomarkers, Tumor - blood ; Care and treatment ; CD4 antigen ; CD8 antigen ; Chronic illnesses ; Complications and side effects ; Cytokines ; Disease control ; Disease transmission ; Drug Therapy, Combination ; Drugs ; Emtricitabine ; Evaluation ; Female ; Health aspects ; Health informatics ; Hepatitis ; Highly active antiretroviral therapy ; HIV ; HIV infection ; HIV Infections - blood ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Infections - virology ; HIV-1 - drug effects ; HIV-1 - physiology ; Hospitals ; Human immunodeficiency virus ; Humans ; Immune response ; Immunology ; Immunosuppressive agents ; Infections ; Infectious diseases ; Integrase ; Interleukin 10 ; Interleukin 13 ; Interleukin 21 ; Interleukin 4 ; Interleukin-10 - blood ; Interleukin-17 - blood ; Interleukin-4 - blood ; Interleukins ; Interleukins - blood ; Lamivudine ; Lymphocytes T ; Male ; Markers ; Medical diagnosis ; Medicine ; Medicine and health sciences ; Middle Aged ; Mortality ; Patient outcomes ; Patients ; Pharmacy ; Physicians ; Pilot Projects ; Prospective Studies ; Protease inhibitors ; Proteinase inhibitors ; Proteins ; Public health ; Standard of Care ; Statistical analysis ; Tenofovir ; Treatment Outcome ; Viral infections ; Viral Load - drug effects ; Viruses ; Young Adult</subject><ispartof>PloS one, 2021-11, Vol.16 (11), p.e0260007-e0260007</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Jianu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Jianu et al 2021 Jianu et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c641t-1641cfe9822d43b76be44fa1c2cffea4e84f708d02a1bbbdc2a0be5813ac547b3</cites><orcidid>0000-0002-2342-4311</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594820/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594820/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34784398$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Apetrei, Cristian</contributor><creatorcontrib>Jianu, Cristian</creatorcontrib><creatorcontrib>Itu-Mureşan, Corina</creatorcontrib><creatorcontrib>Drugan, Cristina</creatorcontrib><creatorcontrib>Filipescu, Irina</creatorcontrib><creatorcontrib>Topan, Adriana Violeta</creatorcontrib><creatorcontrib>Jianu, Mihaela Elena</creatorcontrib><creatorcontrib>Morar, Ioana Iulia</creatorcontrib><creatorcontrib>Bolboacă, Sorana D</creatorcontrib><title>Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoproxil or Lamivudine/Tenofovir disoproxil, NRTI) on four interleukins (IL-4, IL-10, IL-13, and IL-21) as immune activation markers in naïve HIV(Human Immunodeficiency Virus)-infected patients during the first six months of combined standard-of-care antiretroviral therapy (cART). Newly diagnosed with HIV-infected subjects and without any disease that could affect the immune activation markers were evaluated. The patients' physicians recommended the cART as standard-of-care and the ILs were measured before cART and six months of cART. The levels of CD4+ T-cells count and CD4+/CD8+ ratio significantly increased at six months (P-value<0.02) regardless of the drugs, INSTIs or PI. However, a CD4+/CD8+ >1 was observed in 25% of patients treated with Raltegravir and half of those treated with Dolutegravir. At six months of cART, viral load was detectable in only 6/31 individuals. IL-21 had an undetectable level in 30/31 patients after six months of cART. Our results suggest the potency in restoring immune markers in HIV-infected patients with all investigated drugs. Dolutegravir showed a tendency to statistically significant changes in IL-4 and IL-10. A clinical trial with random allocation of medication and an extensive follow-up is needed to replicate this research and validate the usefulness of evaluated ILs as markers of cART effectiveness.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>Anti-HIV agents</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - pharmacology</subject><subject>Bacterial infections</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Care and treatment</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Chronic illnesses</subject><subject>Complications and side effects</subject><subject>Cytokines</subject><subject>Disease control</subject><subject>Disease transmission</subject><subject>Drug Therapy, Combination</subject><subject>Drugs</subject><subject>Emtricitabine</subject><subject>Evaluation</subject><subject>Female</subject><subject>Health aspects</subject><subject>Health informatics</subject><subject>Hepatitis</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV infection</subject><subject>HIV Infections - blood</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - physiology</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunology</subject><subject>Immunosuppressive agents</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Integrase</subject><subject>Interleukin 10</subject><subject>Interleukin 13</subject><subject>Interleukin 21</subject><subject>Interleukin 4</subject><subject>Interleukin-10 - blood</subject><subject>Interleukin-17 - blood</subject><subject>Interleukin-4 - blood</subject><subject>Interleukins</subject><subject>Interleukins - blood</subject><subject>Lamivudine</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Markers</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine and health sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Pharmacy</subject><subject>Physicians</subject><subject>Pilot Projects</subject><subject>Prospective Studies</subject><subject>Protease inhibitors</subject><subject>Proteinase inhibitors</subject><subject>Proteins</subject><subject>Public health</subject><subject>Standard of Care</subject><subject>Statistical analysis</subject><subject>Tenofovir</subject><subject>Treatment Outcome</subject><subject>Viral infections</subject><subject>Viral Load - drug effects</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk81u1DAQxyMEomXhDRBYQkJw2MV2nMThgLSqCl2pUiU-erUcZ7Lr1okX21nRC6_EQ_BiOGxabVAPKFLsjH__mcyMJ0meE7wgaUHeXdneddIstraDBaY5xrh4kByTMqXznOL04cH-KHni_RXGWcrz_HFylLKCs7Tkx8nP0500vQzadsg2yMMOnDRxdX2LdBfAGeivdeeR9KiV7hqcR411KDiQoYUuIGgaUEHvoAPvowZ18vevHaCz1WX8Gs6gRtsYIsL-PVqirTY2IB_6-uZp8qiRxsOzcZ0l3z6efj05m59ffFqdLM_nKmckzEl8qwZKTmnN0qrIK2CskURRFYNLBpw1BeY1ppJUVVUrKnEFGSepVBkrqnSWvNz73RrrxVg6L2hWcpwzivNIrPZEbeWV2Dodk70RVmrx12DdWkgXtDIgSEmKRilo6rJgJWMS53lZyYpDrVityujrwxitr9pojInHok6cTk86vRFruxM8KxmP_Zolb0YHzn7vwQfRaq_AGNmB7ff_nTGSZQP66h_0_uxGai1jArErNsZVg1OxzDktshRTGqnFPVR8ami1ives0dE-EbydCCIT4EdYy957sfry-f_Zi8sp-_qA3YA0YeOt6Ydr6qcg24PKWe8dNHdFJlgMY3JbDTGMiRjHJMpeHDboTnQ7F-kfNtAQvQ</recordid><startdate>20211116</startdate><enddate>20211116</enddate><creator>Jianu, Cristian</creator><creator>Itu-Mureşan, Corina</creator><creator>Drugan, Cristina</creator><creator>Filipescu, Irina</creator><creator>Topan, Adriana Violeta</creator><creator>Jianu, Mihaela Elena</creator><creator>Morar, Ioana Iulia</creator><creator>Bolboacă, Sorana D</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2342-4311</orcidid></search><sort><creationdate>20211116</creationdate><title>Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study</title><author>Jianu, Cristian ; Itu-Mureşan, Corina ; Drugan, Cristina ; Filipescu, Irina ; Topan, Adriana Violeta ; Jianu, Mihaela Elena ; Morar, Ioana Iulia ; Bolboacă, Sorana D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c641t-1641cfe9822d43b76be44fa1c2cffea4e84f708d02a1bbbdc2a0be5813ac547b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>Anti-HIV agents</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - pharmacology</topic><topic>Bacterial infections</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Care and treatment</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Chronic illnesses</topic><topic>Complications and side effects</topic><topic>Cytokines</topic><topic>Disease control</topic><topic>Disease transmission</topic><topic>Drug Therapy, Combination</topic><topic>Drugs</topic><topic>Emtricitabine</topic><topic>Evaluation</topic><topic>Female</topic><topic>Health aspects</topic><topic>Health informatics</topic><topic>Hepatitis</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV infection</topic><topic>HIV Infections - blood</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - physiology</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunology</topic><topic>Immunosuppressive agents</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Integrase</topic><topic>Interleukin 10</topic><topic>Interleukin 13</topic><topic>Interleukin 21</topic><topic>Interleukin 4</topic><topic>Interleukin-10 - blood</topic><topic>Interleukin-17 - blood</topic><topic>Interleukin-4 - blood</topic><topic>Interleukins</topic><topic>Interleukins - blood</topic><topic>Lamivudine</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Markers</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine and health sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Pharmacy</topic><topic>Physicians</topic><topic>Pilot Projects</topic><topic>Prospective Studies</topic><topic>Protease inhibitors</topic><topic>Proteinase inhibitors</topic><topic>Proteins</topic><topic>Public health</topic><topic>Standard of Care</topic><topic>Statistical analysis</topic><topic>Tenofovir</topic><topic>Treatment Outcome</topic><topic>Viral infections</topic><topic>Viral Load - drug effects</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jianu, Cristian</creatorcontrib><creatorcontrib>Itu-Mureşan, Corina</creatorcontrib><creatorcontrib>Drugan, Cristina</creatorcontrib><creatorcontrib>Filipescu, Irina</creatorcontrib><creatorcontrib>Topan, Adriana Violeta</creatorcontrib><creatorcontrib>Jianu, Mihaela Elena</creatorcontrib><creatorcontrib>Morar, Ioana Iulia</creatorcontrib><creatorcontrib>Bolboacă, Sorana D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jianu, Cristian</au><au>Itu-Mureşan, Corina</au><au>Drugan, Cristina</au><au>Filipescu, Irina</au><au>Topan, Adriana Violeta</au><au>Jianu, Mihaela Elena</au><au>Morar, Ioana Iulia</au><au>Bolboacă, Sorana D</au><au>Apetrei, Cristian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-11-16</date><risdate>2021</risdate><volume>16</volume><issue>11</issue><spage>e0260007</spage><epage>e0260007</epage><pages>e0260007-e0260007</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoproxil or Lamivudine/Tenofovir disoproxil, NRTI) on four interleukins (IL-4, IL-10, IL-13, and IL-21) as immune activation markers in naïve HIV(Human Immunodeficiency Virus)-infected patients during the first six months of combined standard-of-care antiretroviral therapy (cART). Newly diagnosed with HIV-infected subjects and without any disease that could affect the immune activation markers were evaluated. The patients' physicians recommended the cART as standard-of-care and the ILs were measured before cART and six months of cART. The levels of CD4+ T-cells count and CD4+/CD8+ ratio significantly increased at six months (P-value<0.02) regardless of the drugs, INSTIs or PI. However, a CD4+/CD8+ >1 was observed in 25% of patients treated with Raltegravir and half of those treated with Dolutegravir. At six months of cART, viral load was detectable in only 6/31 individuals. IL-21 had an undetectable level in 30/31 patients after six months of cART. Our results suggest the potency in restoring immune markers in HIV-infected patients with all investigated drugs. Dolutegravir showed a tendency to statistically significant changes in IL-4 and IL-10. A clinical trial with random allocation of medication and an extensive follow-up is needed to replicate this research and validate the usefulness of evaluated ILs as markers of cART effectiveness.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34784398</pmid><doi>10.1371/journal.pone.0260007</doi><orcidid>https://orcid.org/0000-0002-2342-4311</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-11, Vol.16 (11), p.e0260007-e0260007 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2598064206 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS) Journals Open Access; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Acquired immune deficiency syndrome Adult AIDS Anti-HIV agents Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antiviral agents Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Bacterial infections Biology and Life Sciences Biomarkers, Tumor - blood Care and treatment CD4 antigen CD8 antigen Chronic illnesses Complications and side effects Cytokines Disease control Disease transmission Drug Therapy, Combination Drugs Emtricitabine Evaluation Female Health aspects Health informatics Hepatitis Highly active antiretroviral therapy HIV HIV infection HIV Infections - blood HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology HIV-1 - drug effects HIV-1 - physiology Hospitals Human immunodeficiency virus Humans Immune response Immunology Immunosuppressive agents Infections Infectious diseases Integrase Interleukin 10 Interleukin 13 Interleukin 21 Interleukin 4 Interleukin-10 - blood Interleukin-17 - blood Interleukin-4 - blood Interleukins Interleukins - blood Lamivudine Lymphocytes T Male Markers Medical diagnosis Medicine Medicine and health sciences Middle Aged Mortality Patient outcomes Patients Pharmacy Physicians Pilot Projects Prospective Studies Protease inhibitors Proteinase inhibitors Proteins Public health Standard of Care Statistical analysis Tenofovir Treatment Outcome Viral infections Viral Load - drug effects Viruses Young Adult |
| title | Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T02%3A26%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20several%20serum%20interleukins%20as%20markers%20for%20treatment%20effectiveness%20in%20na%C3%AFve%20HIV%20infected%20patients:%20A%20pilot%20study&rft.jtitle=PloS%20one&rft.au=Jianu,%20Cristian&rft.date=2021-11-16&rft.volume=16&rft.issue=11&rft.spage=e0260007&rft.epage=e0260007&rft.pages=e0260007-e0260007&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0260007&rft_dat=%3Cgale_plos_%3EA682753022%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2598064206&rft_id=info:pmid/34784398&rft_galeid=A682753022&rft_doaj_id=oai_doaj_org_article_1917fccefd974944a0669bab8edc4dc9&rfr_iscdi=true |